HomeCompareRAFA vs KMB

RAFA vs KMB: Dividend Comparison 2026

RAFA yields 3030.30% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAFA wins by $500360607186.77M in total portfolio value
10 years
RAFA
RAFA
● Live price
3030.30%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$500360607186.81M
Annual income
$469,859,227,990,298,900.00
Full RAFA calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — RAFA vs KMB

📍 RAFA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAFAKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAFA + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RAFA pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAFA
Annual income on $10K today (after 15% tax)
$257,575.76/yr
After 10yr DRIP, annual income (after tax)
$399,380,343,791,754,050.00/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, RAFA beats the other by $399,380,343,791,749,600.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAFA + KMB for your $10,000?

RAFA: 50%KMB: 50%
100% KMB50/50100% RAFA
Portfolio after 10yr
$250180303593.43M
Annual income
$234,929,613,995,152,030.00/yr
Blended yield
93.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

RAFA
No analyst data
Altman Z
3.1
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAFA buys
0
KMB buys
0
No recent congressional trades found for RAFA or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAFAKMB
Forward yield3030.30%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$500360607186.81M$45.9K
Annual income after 10y$469,859,227,990,298,900.00$5,211.33
Total dividends collected$498252908594.85M$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RAFA vs KMB ($10,000, DRIP)

YearRAFA PortfolioRAFA Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$313,730$303,030.30$11,314$613.68+$302.4KRAFA
2$9,220,718$8,885,026.99$12,865$759.19+$9.21MRAFA
3$253,918,671$244,052,501.99$14,709$943.96+$253.90MRAFA
4$6,552,701,214$6,281,008,236.19$16,919$1,180.17+$6552.68MRAFA
5$158,496,977,633$151,485,587,333.73$19,588$1,484.33+$158496.96MRAFA
6$3,594,020,691,580$3,424,428,925,512.90$22,838$1,879.06+$3594020.67MRAFA
7$76,416,745,778,469$72,571,143,638,478.27$26,832$2,395.60+$76416745.75MRAFA
8$1,523,841,939,473,922$1,442,076,021,490,960.80$31,788$3,077.63+$1523841939.44MRAFA
9$28,505,961,865,899,772$26,875,450,990,662,680.00$38,000$3,986.82+$28505961865.86MRAFA
10$500,360,607,186,811,600$469,859,227,990,298,900.00$45,872$5,211.33+$500360607186.77MRAFA

RAFA vs KMB: Complete Analysis 2026

RAFAStock

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Full RAFA Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this RAFA vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAFA vs SCHDRAFA vs JEPIRAFA vs ORAFA vs KORAFA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.